FOLH1 and metastatic prostate carcinoma: Specifically for metastatic prostate cancer (mPC), there have been advancements in the development of diagnostic ligands like the 68Ga-PSMA ligands for PET imaging and therapeutic ligands such as 177Lu-PSMA-617 15, 18 (Figure 5).